Prothena

Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Prothena reports robust earnings, advances Alzheimer's treatments with promising results

Prothena's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements in neurodegenerative diseases, and promising results in key programs like PRX012 and Birtamimab.
Challenges include navigating reimbursement changes, dosing complexities, and ensuring accelerated approval pathways for Alzheimer's treatments.
Opportunities lie in leveraging financial strength for pipeline expansion, upcoming data releases, innovative treatment approaches, and establishing leadership in niche disease areas.
Overall, Prothena's strategic focus on innovative therapies and deep understanding of disease mechanisms position the company for continued growth and clinical success.

Prothena reports robust financials and promising clinical advancements in Q4

Prothena's Q4 2023 earnings call highlighted strong financials, progress in key clinical programs, and promising results in movement disorder studies.
While facing challenges in patient enrollment and dose optimization, the company's focus on specialized therapies and patient-centric development positions it well for future growth.
Opportunities lie in optimizing dosing strategies, enhancing treatment efficacy, and leveraging exposure response data to drive innovation and improve therapeutic outcomes.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Vertex Pharmaceuticals

VRTX vs. PRTA: Which Stock Is the Better Value Option?

Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Prothena (PRTA) to Report Q3 Results: Wall Street Expects Earnings Growth

Prothena (PRTA) has promising candidates for Alzheimer's disease in its pipeline. The successful development of the candidates will be a big boost for the company.

Prothena (PRTA) Riding High on Alzheimer's Disease Pipeline

VRTX vs. PRTA: Which Stock Should Value Investors Buy Now?

Expanded roles support the continued transition to a fully integrated biotechnology company focused on rare peripheral amyloid and neurodegenerative diseases Expanded roles support the continued transition to a fully integrated biotechnology company focused on rare peripheral amyloid and neurodegenerative diseases

Prothena Announces Executive Appointments

Promising drug candidates could lead to a best-in-class Alzheimer's treatment.

With Prothena Up Over 500% This Year, Is It Too Late to Get in?

Does Prothena (PRTA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Prothena (PRTA) is a Great Momentum Stock to Buy

DUBLIN, Ireland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that in connection with hiring a new employee, the compensation committee of the Company's board of directors granted the individual hired by the Company an option to purchase 75,000 ordinary shares of the Company. The option has an exercise price per share equal to $69.88, which was the closing trading price on September 1, 2021, the date of the grant. The option will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the date of grant and 1/48th of the underlying shares vesting monthly thereafter over 36 months. The option was granted pursuant to the Company's 2020 Employment Inducement Incentive Plan, which was approved by the Company's board of directors under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in the following September investor conferences:

Prothena to Participate in Upcoming September Healthcare Conferences

Prothena (PRTA) surges substantially in the past three months on solid prospects of its AD candidates following Biogen???s AD drug approval.

Here is Why Prothena (PRTA) is Up More Than 155% in Three Months

Prothena's (PRTA) earnings for the second quarter of 2021 beat estimates. Its pipeline remains in focus as the company expects to receive milestone payments from partners.

Prothena (PRTA) Q2 Earnings Top Estimates, Pipeline in Focus

Prothena (PRTA) delivered earnings and revenue surprises of 1.75% and -0.12%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Prothena (PRTA) Q2 Earnings Top Estimates

Shares of Prothena Corp (NASDAQ:PRTA) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 187.88% year over year to $0.58, which beat the estimate of $0.55.

Recap: Prothena Corp Q2 Earnings

DUBLIN, Ireland, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today reported financial results for the second quarter and first six months of 2021. In addition, the Company provided business highlights and updated 2021 financial guidance.

Prothena Reports Second Quarter 2021 Financial Results and Business Highlights

Prothena (PRTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Prothena (PRTA) Earnings Expected to Grow: What to Know Ahead of Q2 Release

DUBLIN, Ireland, July 29, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, announced today that it will report its second quarter and first six months of 2021 financial results on Thursday, August 5, 2021 after the close of the U.S. financial markets.

Prothena to Report Second Quarter 2021 Financial Results on August 5th

Novo Nordisk

The company is mainly known for its diabetes drugs but has some background in rare-disease drugs.

Why Is Novo Nordisk Buying a Rare-Disease Candidate?

Prothena is a $2.25bn market cap biotech with a unique, epitope targeting approach to drug development. The company has resurrected its AL Amyloidosis drug Birtamimab and has a pivotal trial ongoing in high risk patients.

Prothena: Underrated Player In Alzheimer's And Parkinson's Close To Securing First Drug Approval

Annovis Bio

Eli Lilly

Treating Alzheimer's is extremely difficult, but these innovative companies are taking a stab at it.

Got $2,500? Check Out These 3 Alzheimer's Therapy Stocks

Prothena Corp (NASDAQ:PRTA) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 2 0 2 0 Somewhat Bullish 1 0 1 0 Indifferent 0 1 0 0 Somewhat Bearish 0 0 0 0 Bearish 0 0 0 0 In the last 3 months, 7 analysts have offered 12-month price targets for Prothena Corp. The company has an average price target of $59.86 with a high of $76.00 and a low of $39.00.

Where Prothena Corp Stands With Analysts

Prothena (PRTA) announces an agreement to sell its clinical-stage antibody, PRX004, and the broader ATTR amyloidosis program for $1.2 billion to Novo Nordisk.

Prothena (PRTA) to Sell ATTR Amyloidosis Program to Novo Nordisk

Novo Nordisk A/S (NYSE: NVO) will acquire Prothena Corporation plc's  (NASDAQ: PRTA) and clinical stage antibody PRX004 and broader ATTR amyloidosis program. PRX004 is a Phase 2 ready immunotherapy designed to deplete the amyloid deposits associated with the disease pathology of ATTR amyloidosis.

Novo Nordisk To Buy Prothena's ATTR Amyloidosis Program For Up To $1.2B

Shares of Prothena Corp. Plc were up 1.3% in premarket trading on Monday after the company announced a deal to sell its ATTR amyloidosis portfolio to Novo Nordisk in a $100 million deal that is worth up to $1.2 billion, based on milestones. ATTR amyloidosis is a rare disease that can cause a buildup of amyloid deposits in the body.

Prothena sells amyloidosis portfolio to Novo Nordisk for up to $1.2 billion

Danish drugmaker Novo Nordisk will acquire U.S. drug developer Prothena Corp's experimental heart therapy, PRX004, in a deal that could be worth up to $1.23 billion, the companies said on Monday.

Novo Nordisk to buy Prothena's heart drug in deal worth up to $1.2 billion

DUBLIN, Ireland and BAGSVÆRD, Denmark, July 12, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA) and Novo Nordisk A/S (Nasdaq Copenhagen: NOVO B) today announced that the companies have entered into a definitive purchase agreement under which Novo Nordisk has acquired Prothena's clinical stage antibody PRX004 and broader ATTR amyloidosis programme.

News for Prothena Stock (PRTA)